We're cutting our price target on Danaher as frustration mounts after a messy quarter
Trump signs sweeping order to further restrict trans care for minors nationwide
23andMe is exploring strategic alternatives, looking to raise capital
Healthy Returns: Trump made sweeping changes to health care in his first week
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Food-as-medicine startups hope Kennedy, if confirmed as HHS secretary, will boost their businesses
We're trimming a 2025 top gainer, taking profits on the market's rotation into health stocks
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
